CORONA Remedies Limited
CORONA Remedies Limited (CORONA) financial statements and selected valuation metrics from NSE/BSE exchange filings through 30 June 2026.
Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals
coronaremedies.com(opens the company website in a new tab)Key metrics
Price as of 2026-09-03
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Sales | 361 Cr | 342 Cr | 353 Cr | 422 Cr |
| Operating expenses (approx.) | 283 Cr | 259 Cr | 291 Cr | 329 Cr |
| EBITDA | 78 Cr | 83 Cr | 62 Cr | 93 Cr |
| OPM % | 21.7% | 24.3% | 17.6% | 22.0% |
| Other income | 2 Cr | 2 Cr | 4 Cr | 3 Cr |
| Interest | 2 Cr | 2 Cr | 1 Cr | 3 Cr |
| Depreciation | 9 Cr | 9 Cr | 10 Cr | 13 Cr |
| Profit before tax | 70 Cr | 55 Cr | 55 Cr | 80 Cr |
| Tax % | 25.0% | 25.2% | 17.2% | 25.2% |
| Net profit | 52 Cr | 41 Cr | 45 Cr | 60 Cr |
| EPS (₹) | ₹8.55 | ₹6.75 | ₹7.41 | ₹9.83 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2026 | TTM |
|---|---|---|
| Sales | 1,403 Cr | Sign in for TTM |
| Operating expenses (approx.) | 1,110 Cr | Sign in for TTM |
| EBITDA | 293 Cr | Sign in for TTM |
| OPM % | 20.9% | Sign in for TTM |
| Other income | 11 Cr | Sign in for TTM |
| Interest | 7 Cr | Sign in for TTM |
| Depreciation | 38 Cr | Sign in for TTM |
| Profit before tax | 240 Cr | Sign in for TTM |
| Tax % | 23.0% | Sign in for TTM |
| Net profit | 185 Cr | Sign in for TTM |
| EPS (₹) | ₹30.27 | Sign in for TTM |
| Dividend payout % | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2026 |
|---|---|
| Equity capital | 61 Cr |
| Reserves | 686 Cr |
| Borrowings | 143 Cr |
| Other liabilities | 315 Cr |
| Total liabilities | 1,205 Cr |
| Fixed assets (net) | 291 Cr |
| CWIP | 143 Cr |
| Investments | 26 Cr |
| Loans & advances | 0.26 Cr |
| Inventories | 125 Cr |
| Trade receivables | 146 Cr |
| Cash & bank | 2 Cr |
| Other assets | 472 Cr |
| Total assets | 1,205 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2026 |
|---|---|
| Cash from operating activity | 229 Cr |
| Cash from investing | -256 Cr |
| Cash from financing | 25 Cr |
| Net cash flow | -1 Cr |
| Free cash flow (OCF − Capex) | 55 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2026 |
|---|---|
| ROCE % | 27.8% |
| ROE % | 24.8% |
| Debtor days | 38 |
| Inventory days | 440 |
| Days payable | 517 |
| Cash conversion cycle | -40 |
| Debt / equity | 0.19 |
| Current ratio | 0.96 |
| Net debt / EBITDA | 0.48 |
Compare with peers
Loading peers…